Frank Vinluan from MedCity News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation		Merck Is Embracing AI, But ‘We Always Have a Human in the Loop,’ Exec Says - 6 days ago Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma - 8 days ago Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash - 9 days ago FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZeneca - 10 days ago Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots - 11 days ago Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug - 12 days ago Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline - 13 days ago Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma - 15 days ago Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval - 16 days ago Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects - 17 days ago Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval - 18 days ago Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval - 19 days ago Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - 20 days ago Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds - 23 days ago FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer - about 1 month ago Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation - about 1 month ago At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected - about 1 month ago J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies - about 1 month ago Galapagos Keeps Focus on Cancer Cell Therapy, Spins Out Rest of Biz Into NewCo Backed by €2.4B - about 2 months ago Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - about 2 months ago Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health - about 2 months ago A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly - about 2 months ago FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions - about 2 months ago Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing - about 2 months ago Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - about 2 months ago Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug - about 2 months ago The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - about 2 months ago Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies - 2 months ago Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea - 2 months ago Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds - 2 months ago Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug - 2 months ago Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - 2 months ago Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site - 2 months ago ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - 2 months ago AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots - 2 months ago Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - 2 months ago GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH - 3 months ago Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug - 3 months ago Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease - 3 months ago Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test - 3 months ago Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - 3 months ago Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug - 3 months ago Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease - 3 months ago Startup OncoSwab Aims to Make Lung Cancer Detection as Simple as Flu & Covid-19 Tests - 3 months ago Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - 3 months ago Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - 3 months ago FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - 3 months ago Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy - 3 months ago Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - 3 months ago Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - 3 months ago